TTF-1 甲狀腺轉(zhuǎn)錄因子1（克隆號(hào)SPT24）

廣州健侖生物科技有限公司

TTF-1表達(dá)于甲狀腺腺上皮和肺上皮細(xì)胞中。肺腫瘤研究發(fā)現(xiàn)，大多數(shù)肺小細(xì)胞癌、肺腺癌、小部分未分化大細(xì)胞肺癌和非典型類癌、少數(shù)典型類癌表達(dá)TTF-1，而肺鱗癌不表達(dá)。在甲狀腺乳頭狀腺癌中TTF-1也呈陽(yáng)性，而TTF-1在其它組織均陰性表達(dá)。因此，TTF-1可用來研究肺腺癌和鱗癌，并有助于肺腺癌轉(zhuǎn)移至肺外部位的研究。

我司還提供其它進(jìn)口或國(guó)產(chǎn)試劑盒：登革熱、瘧疾、流感、A鏈球菌、合胞病毒、腮病毒、乙腦、寨卡、黃熱病、基孔肯雅熱、克錐蟲病、違禁品濫用、肺炎球菌、軍團(tuán)菌、化妝品檢測(cè)、食品安全檢測(cè)等試劑盒以及日本生研細(xì)菌分型診斷血清、德國(guó)SiFin診斷血清、丹麥SSI診斷血清等產(chǎn)品。

歡迎咨詢

歡迎咨詢

TTF-1 甲狀腺轉(zhuǎn)錄因子1（克隆號(hào)SPT24）

【產(chǎn)品介紹】

細(xì)胞定位：細(xì)胞核/細(xì)胞漿

克隆號(hào)：SPT24

同型：IgG

適用組織：石蠟/冰凍

陽(yáng)性對(duì)照：甲狀腺乳頭瘤/肺腺癌/肝癌

抗原修復(fù)：熱修復(fù)（EDTA）

抗體孵育時(shí)間：30-60min

TTF-1

想了解更多的產(chǎn)品及服務(wù)請(qǐng)掃描下方二維碼：

【公司名稱】 廣州健侖生物科技有限公司
【市場(chǎng)部】     歐

【】 
【騰訊  】 
【公司地址】 廣州清華科技園創(chuàng)新基地番禺石樓鎮(zhèn)創(chuàng)啟路63號(hào)二期2幢101-103室

一旦獲得被研究人員稱之為“抗原抗體者”(因?yàn)槠渚哂泄艉痛輾О┘?xì)胞的能力)的細(xì)胞，t細(xì)胞被輸回到病人體內(nèi)進(jìn)行繁殖并攻擊癌細(xì)胞。此外因?yàn)镃AR抗原可以接受控制，研究人員讓細(xì)胞快速繁殖，宛如可以大規(guī)模殺死癌細(xì)胞的“抗原抗體者細(xì)胞*”。事實(shí)上試驗(yàn)顯示，一個(gè)植入細(xì)胞可以在病人身上繁殖出1萬個(gè)新細(xì)胞。
報(bào)道稱，到目前為止，參與試驗(yàn)的19名患者癥狀得到緩解，其中15名患者僅使用了這一種療法，包括一名9歲兒童，他是兩年前*個(gè)接受CTL019療法的病人。所有接受CTL019細(xì)胞的患者在接受細(xì)胞輸入幾天后都出現(xiàn)了細(xì)胞因子釋放綜合征，這是經(jīng)過修改的細(xì)胞在患者體內(nèi)繁殖和攻擊腫瘤細(xì)胞的標(biāo)記，病人癥狀輕重各有不同，表現(xiàn)為流感、高熱、抗原抗體、肌肉疼痛、低血壓和呼吸困難等，但經(jīng)過配合治療zui后這些癥狀在所抗原抗體人身上都會(huì)消失。與此同時(shí)，那些ALL病癥*消除的患者，他們體內(nèi)同樣帶有CD19蛋白的非腫瘤正常B細(xì)胞也隨著腫瘤被一起清除了。研究人員指出，接受CTL019療法后正常B細(xì)胞持續(xù)缺失說明基因改良T細(xì)胞在持續(xù)活動(dòng)，相信它們可以起到類似于預(yù)防腫瘤復(fù)發(fā)的長(zhǎng)期疫苗的作用。

Once cells are known by researchers as "antigen-antibodies" (because of their ability to attack and destroy cancer cells), the t-cells are returned to the patient's body to multiply and attack the cancer cells. In addition, because CAR antigens are under control, researchers are able to multiply cells quickly, just like the "army of antigen-antibody cells" that kill cancer cells on a large scale. In fact, experiments show that one implanted cell produces 10,000 new cells in the patient.
To date, the 19 patients who participated in the trial were relieved of symptoms, 15 of whom used this therapy alone, including a 9-year-old child who was the first patient to receive CTL019 therapy two years earlier. All patients who received CTL019 cells developed cytokine release syndrome a few days after receiving the cell input, a marker of a modified cell that multiplied and attacked the tumor cells in the patient. The patient's symptoms varied in severity, manifested as flu, Fever, antigen and antibody, muscle pain, hypotension and dyspnea, but after the treatment of these symptoms in the final anti-human antibodies will disappear. In the meantime, patients with complete elimination of ALL disease also have non-tumor-normal B cells that also carry CD19 protein in their body cleared with the tumor. The researchers pointed out that the continued absence of normal B cells following CTL019 therapy suggests that the genetically modified T cells are continuously active, believing they can act as long-term vaccines that prevent tumor recurrence.